National Bank of Canada
CPRX

National Bank of Canada’s Catalyst Pharmaceutical CPRX Stock Holding History

National Bank of Canada’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.9K Sell
2,377
-98
-4% -$2.33K ﹤0.01% 1931
2025
Q4 		$57.7K Buy
2,475
+278
+13% +$6.19K ﹤0.01% 1936
2025
Q3 		$43.3K Sell
2,197
-1,956
-47% -$40.2K ﹤0.01% 1973
2025
Q2 		$90.1K Sell
4,153
-51
-1% -$1.2K ﹤0.01% 1809
2025
Q1 		$102K Buy
4,204
+2
+0% +$45 ﹤0.01% 1697
2024
Q4 		$87.7K Sell
4,202
-1,026
-20% -$22K ﹤0.01% 1787
2024
Q3 		$104K Sell
5,228
-272
-5% -$5.04K ﹤0.01% 1527
2024
Q2 		$86.5K Hold
5,500
– – ﹤0.01% 1528
2024
Q1 		$87.6K Buy
+5,500
New +$82.9K ﹤0.01% 1587
2023
Q4 		– Sell
-200
Closed -$2.35K – 2746
2023
Q3 		$2.35K Hold
200
– – ﹤0.01% 2493
2023
Q2 		$2.69K Hold
200
– – ﹤0.01% 2437
2023
Q1 		$3.32K Buy
200
+34
+20% +$561 ﹤0.01% 2361
2022
Q4 		$3.09K Buy
+166
New +$2.56K ﹤0.01% 2420

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

National Bank of Canada's CPRX Position: Q1 2026 in Review

National Bank of Canada reduced its Catalyst Pharmaceutical (CPRX) stake by 4% in Q1 2026, selling an estimated $2.33K and leaving 2,377 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

National Bank of Canada first reported a position in CPRX in Q4 2022 and has held it in 13 quarters since. The position peaked at $104K in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • National Bank of Canada held 2,377 shares of Catalyst Pharmaceutical worth $58.9K as of Q1 2026.
  • National Bank of Canada sold 98 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.33K.
  • Catalyst Pharmaceutical made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1931 holding.
  • National Bank of Canada first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 13 quarters since.
  • National Bank of Canada's Catalyst Pharmaceutical position peaked at $104K in Q3 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.